A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
Var2 Pharmaceuticals
National Cancer Institute (NCI)
Instituto do Cancer do Estado de São Paulo
University Medical Center Groningen
Celgene
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Masonic Cancer Center, University of Minnesota
Dana-Farber Cancer Institute
Valerio Therapeutics
Valerio Therapeutics
INSYS Therapeutics Inc
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Oncology Group
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center